[8-K] Tempest Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Tempest Therapeutics reported that it has issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to this report as Exhibit 99.1. This Form 8-K indicates the company is furnishing the press release rather than "filing" it, meaning the release is provided for investor information in this report but is not subject to the liabilities of being formally filed or automatically incorporated by reference in other Securities Act filings. The 8-K itself does not include the numerical financial statements; those figures are contained in the attached press release.

Insights

Financial Analyst

TL;DR: The company furnished a press release with Q2 2025 results; the 8-K contains no financial figures, so impact cannot be assessed from this filing alone.

The filing communicates that Tempest released its quarterly results for the period ended June 30, 2025 and attached the release as Exhibit 99.1. Because the 8-K only furnishes the press release and does not include the underlying financial statements or metrics, there is insufficient information here to judge revenue, profitability, cash position, or trend changes. Investors must review Exhibit 99.1 for quantitative results and disclosures.

Corporate Governance Expert

TL;DR: The company explicitly furnished the press release rather than filing it, limiting Section 18 liability and incorporation by reference.

The 8-K states the press release is being "furnished" and therefore is not deemed "filed" under the Exchange Act, which is a common procedural distinction that limits certain statutory liabilities and prevents automatic incorporation into future Securities Act filings. The filing also identifies the press release as Exhibit 99.1, but does not present the underlying financial tables within the body of the 8-K. From a governance perspective, this is a routine disclosure mechanism; material assessment requires the attached exhibit.

0001544227false0001544227us-gaap:CommonStockMember2025-08-112025-08-1100015442272025-08-112025-08-110001544227tpst:SeriesAJuniorParticipatingPreferredPurchaseRightsMember2025-08-112025-08-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

Tempest Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-35890	45-1472564
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2000 Sierra Point Parkway, Suite 400
Brisbane, California				94005
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (415) 798-8589

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		TPST		The Nasdaq Stock Market LLC
Series A Junior Participating Preferred Purchase Rights		N/A		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, Tempest Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025 and other business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The foregoing information (including Exhibit 99.1 hereto) is being furnished under “Item 2.02 Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release dated August 11, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			TEMPEST THERAPEUTICS, INC.
Date:	August 11, 2025	By:	/s/ Stephen Brady
		Name:	Stephen Brady
		Title:	Chief Executive Officer

FAQ

What did Tempest Therapeutics (TPST) disclose in this 8-K?

The company disclosed that it issued a press release announcing financial results for the quarter ended June 30, 2025, and attached that release as Exhibit 99.1.

Does this 8-K include the company's financial statements or numeric results?

No. The 8-K furnishes a press release but does not include the detailed financial statements or numeric tables in the filing itself; those figures are in Exhibit 99.1.

Is the press release in this 8-K considered "filed" with the SEC?

No. The filing states the press release is being furnished under Item 2.02 and explicitly says it shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Where can I find the full press release with the financial results?

The full press release is attached to this report as Exhibit 99.1. Review Exhibit 99.1 for the complete quantitative results and business highlights.

Who signed the 8-K for Tempest Therapeutics?

The report was signed on behalf of the registrant by Stephen Brady, Chief Executive Officer.